Fibroblast Growth Factor Receptor 1-Bound Extracellular Vesicle as Novel Therapy for Osteoarthritis

Liyis, Bryan Gervais de; Nolan, John P.; Maharjana, Made Agus

doi:10.37796/2211-8039.1308

Cited by 13 publications

(9 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous proinflammatory mediators are produced during the progression of OA, including IL-1β and TNF-α, leading to the activation of catabolic factors, resulting in cartilage degradation and bone erosion [36,37]. The levels of IL-1β and TNF-α expression in serum and synovial tissue are associated with the pathological process of OA [38,39].…”

Section: Discussionmentioning

confidence: 99%

Hericium erinaceus Mycelium Ameliorates In Vivo Progression of Osteoarthritis

et al. 2022

View full text Add to dashboard Cite

Osteoarthritis (OA) is an age-related disorder that affects the joints and causes functional disability. Hericium erinaceus is a large edible mushroom with several known medicinal functions. However, the therapeutic effects of H. erinaceus in OA are unknown. In this study, data from Sprague-Dawley rats with knee OA induced by anterior cruciate ligament transection (ACLT) indicated that H. erinaceus mycelium improves ACLT-induced weight-bearing asymmetry and minimizes pain. ACLT-induced increases in articular cartilage degradation and bone erosion were significantly reduced by treatment with H. erinaceus mycelium. In addition, H. erinaceus mycelium reduced the synthesis of proinflammatory cytokines interleukin-1β and tumor necrosis factor-α in OA cartilage and synovium. H. erinaceus mycelium shows promise as a functional food in the treatment of OA.

show abstract

Section: Discussionmentioning

confidence: 99%

Hericium erinaceus Mycelium Ameliorates In Vivo Progression of Osteoarthritis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Although all four FGFRs are encoded by different genes, their amino acid sequences share 56–71% similarity. Hypertrophic chondrocytes mainly express FGFR-1 and FGFR-2 and participate in intramembrane osteogenesis [ 94 , 95 ]. Osteoblasts in the ossification center mainly express FGFR-2 [ 96 ] and a small amount of FGFR-1 and FGFR-3 [ 97 ].…”

Section: Bone Growth Factorsmentioning

confidence: 99%

Progress of Wnt Signaling Pathway in Osteoporosis

Gao

Chen

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Osteoporosis, one of the serious health diseases, involves bone mass loss, bone density diminishing, and degeneration of bone microstructure, which is accompanied by a tendency toward bone fragility and a predisposition to fracture. More than 200 million people worldwide suffer from osteoporosis, and the cost of treating osteoporotic fractures is expected to reach at least $25 billion by 2025. The generation and development of osteoporosis are regulated by genetic factors and regulatory factors such as TGF-β, BMP, and FGF through multiple pathways, including the Wnt signaling pathway, the Notch signaling pathway, and the MAPK signaling pathway. Among them, the Wnt signaling pathway is one of the most important pathways. It is not only involved in bone development and metabolism but also in the differentiation and proliferation of chondrocytes, mesenchymal stem cells, osteoclasts, and osteoblasts. Dkk-1 and SOST are Wnt inhibitory proteins that can inhibit the activation of the canonical Wnt signaling pathway and block the proliferation and differentiation of osteoblasts. Therefore, they may serve as potential targets for the treatment of osteoporosis. In this review, we analyzed the mechanisms of Wnt proteins, β-catenin, and signaling molecules in the process of signal transduction and summarized the relationship between the Wnt signaling pathway and bone-related cells. We hope to attract attention to the role of the Wnt signaling pathway in osteoporosis and offer new perspectives and approaches to making a diagnosis and giving treatment for osteoporosis.

show abstract

“…EV therapies may be a promising treatment for OA in peripheral joints and TMJ because of their low immunogenicity, low cytotoxicity, and long-term stability characteristics. Recently, the EVs from modified cells or loaded with drugs showed therapeutic effects in OA ( 182 , 186 , 187 ), which are attractive for this field. There are three forms of EVs, and the recent research of EV therapy mainly focused on exosomes, which showed therapeutic effects in OA treatment ( 188 ).…”

Section: Conclusion and Perspectivementioning

confidence: 99%

Extracellular vesicles in osteoarthritis of peripheral joint and temporomandibular joint

Yang

Li²,

Fu³

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

Osteoarthritis (OA) is a disabling disease with significant morbidity worldwide. OA attacks the large synovial joint, including the peripheral joints and temporomandibular joint (TMJ). As a representative of peripheral joint OA, knee OA shares similar symptoms with TMJ OA. However, these two joints also display differences based on their distinct development, anatomy, and physiology. Extracellular vesicles (EVs) are phospholipid bilayer nanoparticles, including exosomes, microvesicles, and apoptotic bodies. EVs contain proteins, lipids, DNA, micro-RNA, and mRNA that regulate tissue homeostasis and cell-to-cell communication, which play an essential role in the progression and treatment of OA. They are likely to partake in mechanical response, extracellular matrix degradation, and inflammatory regulation during OA. More evidence has shown that synovial fluid and synovium-derived EVs may serve as OA biomarkers. More importantly, mesenchymal stem cell-derived EV shows a therapeutic effect on OA. However, the different function of EVs in these two joints is largely unknown based on their distinct biological characteristic. Here, we reviewed the effects of EVs in OA progression and compared the difference between the knee joint and TMJ, and summarized their potential therapeutic role in the treatment of OA.

show abstract

Fibroblast Growth Factor Receptor 1-Bound Extracellular Vesicle as Novel Therapy for Osteoarthritis

Cited by 13 publications

References 90 publications

Hericium erinaceus Mycelium Ameliorates In Vivo Progression of Osteoarthritis

Hericium erinaceus Mycelium Ameliorates In Vivo Progression of Osteoarthritis

Progress of Wnt Signaling Pathway in Osteoporosis

Extracellular vesicles in osteoarthritis of peripheral joint and temporomandibular joint

Contact Info

Product

Resources

About